Biotech News
Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
-Phase 1 ELIMINATE-B study successful, PBGENE-HBV Program Advancing to Phase 2- -PBGENE-HBV achieves target product profile at 0.4 mg/kg dose- -PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients at expected go-forward dose of 0.4 mg/kg; Durable and ongoing pgRNA loss in
